KORTUC technology is not yet approved by a regulatory authority in any country.
The GCP based clinical trial for KORTUC technology is underway in the United Kingdom at several hospitals led by the Royal Marsden Hospital in London. The description of the ongoing Phase 2 trial for locally advanced breast cancer can be found in the ClinicalTrials.gov website.
The outcome of the Phase 1 trial was published online on the Red Journal on June 21, 2020.
We believe that KORTUC, radiosensitizer, can be applied to any type of solid tumor for which radiation therapy is indicated. We will conduct clinical trials to make its indication much broader and to make it available globally.